10.03.2017
Medios AG DE000A1MMCC8
Medios AG welcomes the new German Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance (AMVSG)
DGAP-Media / 10.03.2017 / 09:30
Press release
Medios AG welcomes the new German Act on Strengthening Pharmaceutical Supply
in Statutory Health Insurance (AMVSG)
- German parliament passes the new German Act on Strengthening
Pharmaceutical Supply in Statutory Health Insurance (AMVSG).
- Public tendering on cytostatic drugs banned and abolition of exclusive
cytostatic drug agreements will give insurance policyholders more freedom in
the choice of their pharmacies.
- Manfred Schneider, CEO of Medios AG says, "In the past, prices were the
main thing that mattered in public tenders of the health insurance companies
for cytostatic drugs. Now the focus is finally shifting to quality. The new
law will improve not only the healthcare of patients but also the growth
opportunities of Medios AG."
- Medios expects to further pursue its growth strategy in fiscal year 2017.
Berlin, March 10, 2017 - Medios AG, an expert pharmaceutical partner and
solution provider in the Specialty Pharma segment, welcomes the new German
Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance
(AMVSG), which was passed yesterday by the German parliament and is expected
to enter into force in May 2017.
AMVSG will improve healthcare in Germany. It mostly affects people with
chronic or genetic illnesses like cancer. Because these patients have a
great need for cytostatic drugs that are delivered flexibly, safely, and
locally, the law prohibits public tendering on cytostatic drugs and at the
same time abolishes exclusive cytostatic drug agreements between health
insurance companies and pharmacies. This would give insurance policyholders
more freedom in the choice of their pharmacies.
Manfred Schneider, CEO of Medios AG: "In the past, prices were the main
thing that mattered in public tenders of the health insurance companies for
cytostatic drugs. Now the focus is finally shifting to quality. The new law
will improve not only the healthcare of patients but also the growth
opportunities of Medios AG. As a leading expert partner and solution
provider for Specialty Pharma, we establish the benchmarks for personalized
medicine. Thanks to our many years of experience and our comprehensive
network, we are able to efficiently produce for example individualised
cytostatic infusions while providing high quality and leveraging scales of
economy. In Berlin, the city with the lowest reimbursement prices, we
already have a 30% market share."
Thanks to high demand for personalized medicine, Medios grew significantly
in fiscal year 2016. According to preliminary consolidated calculations (pro
forma, IFRS), sales revenue for the corporate group increased by 78%
year-over-year to EUR 160.5 million (prior year EUR 90.1 million), thus
exceeding market expectations. The operating result (EBIT) climbed
disproportionately by 100.4% to EUR 5.67 million (prior year EUR 2.83
million). This improved profitability as the EBIT margin rose to 3.53%
(prior year 3.14%).
For fiscal year 2017, the Management Board of Medios expects to further
pursue its growth strategy due to market opportunities developing in the
area of personalized medicine and regulatory actions related to AMVSG.
About Medios AG
Medios AG positions itself - along with its sister companies Medios Pharma,
Medios Manufaktur and Medios Digital - as a competence partner and solution
provider for the Specialty Pharma sector. Medios AG interconnects individual
actors within the market and turns them into co-operating partners. It is
our goal to guarantee best possible pharmaceutical care for patients while
providing our partners and clients with integrated solutions along the
supply chain. Specialty Pharma medicine are pharmaceuticals for patients
with rare and chronic diseases such as certain cancer types and autoimmune /
infectious diseases, which are time-consuming and cost-intensive to cure.
Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Herrengraben 1
20459 Hamburg
Telefon: +49 40 60918618
Fax: +49 60918660
E-mail: [email protected]
www.kirchhoff.de
Disclaimer
This notification contains forward-looking statements that are subject to
certain risks and uncertainties. Future results may significantly deviate
from currently expected results, specifically due to various risk factors
and uncertainties such as changes in business, economic, and competitive
circumstances, exchange rate fluctuations, uncertainties about legal
disputes or investigations, and the availability of financial resources.
Medios AG assumes no responsibility whatsoever for updating the
forward-looking statements contained in this notification.
End of Media Release
---------------------------------------------------------------------------
Issuer: Medios AG
Key word(s): Enterprise
10.03.2017 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: 030 / 8321 8377
E-mail: [email protected]
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg;
Regulated Unofficial Market in Dusseldorf
End of News DGAP Media
---------------------------------------------------------------------------
552743 10.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Medios AG ISIN: DE000A1MMCC8 können Sie bei EQS abrufen
Gesundheit , A1MMCC , ILM1 , XETR:ILM1